| Parameters |
Cases (N=26) |
Controls (N=78) |
COR |
95% CI |
p value |
| Gender |
Male |
10 |
29 |
1.0 |
|
|
| Female |
16 |
49 |
0.9 |
0.4-2.2 |
0.726 |
| Age |
15-30 |
6 |
8 |
1.0 |
|
|
| 31-45 |
12 |
45 |
1.7 |
0.5-6.3 |
0.409 |
| >45 |
8 |
23 |
0.8 |
0.3-2.1 |
0.612 |
| BMI |
<18.5 |
20 |
41 |
3.0 |
1.1-8.3 |
0.033 |
| ≥18.5 |
6 |
37 |
1.0 |
|
|
| CD4+ cell count |
<50 |
15 |
22 |
13.0 |
(1.6-107.4)# |
0.018 |
| 51-100 |
4 |
18 |
4.22 |
(0.4-41.5) |
0.216 |
| 101-200 |
6 |
19 |
6.0 |
(0.7-54.8) |
0.112 |
| >200 |
1 |
19 |
1.0 |
|
|
| Type of TB |
SPPTB |
10 |
55 |
1.0 |
|
|
| SNPTB |
3 |
9 |
1.8 |
0.4-7.9 |
0.419 |
| EPTB |
13 |
14 |
5.1 |
1.8-14.0 |
0.002 |
| Hepatitis B co-infection |
No |
19 |
74 |
1.0 |
|
|
| Yes |
7 |
4 |
6.8 |
1.8-25.7 |
0.005 |
| ARV treatment |
No |
7 |
28 |
1.0 |
|
|
| Yes |
19 |
50 |
1.5 |
0.5-4.1 |
0.403 |
| ARV Regimen |
EFV-based |
7 |
18 |
1 |
|
|
| NVP based |
11 |
29 |
0.9 |
0.3-3.0 |
0.965 |
| Boosted PIs |
1 |
3 |
0.9 |
0.76-9.70 |
0.901 |
| WHO HIV/AIDS stage |
Stage 3 |
13 |
64 |
1.0 |
|
|
| Stage 4 |
13 |
14 |
4.6 |
1.7-11.9 |
0.002 |
| Cotrimoxazole |
No |
8 |
32 |
1.0 |
|
|
| Yes |
18 |
46 |
1.6 |
0.6-4.0 |
0.354 |
CI: Confidence interval, COR: Crude Odd Ratio, NVP: nevirapine, EFV: efavirenz,
PIs: Protease inhibitors #CI is so wide that it might not be considered useful in
providing information about the value of CD4+ cells, although the OR is significant |
